
  
    
      
        
        The_DT scientific_JJ strategic_JJ plan_NN of_IN the_DT Global_NNP HIV_NNP /_NN AIDS_NNP Vaccine_NNP Enterprise_NNP ,_, published_VBN in_IN
        this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP ,_, is_VBZ a_DT clear_JJ and_CC cogent_NN document_NN describing_VBG how_WRB major_JJ
        funders_NNS and_CC stakeholders_NNS in_IN HIV_NNP vaccine_NN development_NN should_MD move_VB forward_RB in_IN a_DT collaborative_JJ
        fashion_NN [_NN 1_CD ]_NN ._. There_EX is_VBZ no_DT doubt_NN that_IN this_DT roadmap_NN will_MD be_VB regarded_VBN as_IN a_DT useful_JJ instrument_NN to_TO
        bring_VB greater_JJR cohesion_NN and_CC coordination_NN to_TO the_DT field_NN ._. The_DT individuals_NNS who_WP championed_VBD this_DT
        effort_NN should_MD be_VB commended_JJ for_IN providing_VBG a_DT great_JJ service_NN to_TO the_DT scientific_JJ community_NN ._. It_PRP is_VBZ
        an_DT excellent_JJ start_NN to_TO a_DT continuing_VBG dialogue_NN of_IN utmost_JJ importance_NN ._.
      
      
        The_DT Challenge_NNP
        Why_WRB is_VBZ it_PRP that_IN we_PRP still_RB do_VBP not_RB have_VB a_DT protective_JJ vaccine_NN against_IN HIV_NNP 22_CD years_NNS after_IN its_PRP$
        initial_JJ identification_NN ?_. Many_JJ possible_JJ explanations_NNS come_VBP to_TO mind_VB ._.
        In_IN the_DT natural_JJ course_NN of_IN HIV_NNP infection_NN ,_, the_DT virus_NN wins_VBZ 99_CD %_NN of_IN the_DT time_NN ,_, showing_VBG that_IN
        specific_JJ immunity_NN in_IN an_DT infected_JJ person_NN is_VBZ unable_JJ to_TO completely_RB clear_VB the_DT virus_NN ._. We_PRP have_VBP
        also_RB known_VBN for_IN over_IN a_DT decade_NN that_IN primary_JJ HIV_NNP isolates_VBZ are_VBP relatively_RB resistant_JJ to_TO antibody_NN
        neutralization_NN ,_, probably_RB because_IN of_IN a_DT “ protective_JJ shield_NN” on_IN the_DT viral_JJ envelope_NN
        glycoproteins_NNS ,_, consisting_VBG of_IN variable_JJ loop_NN sequences_NNS and_CC extensive_JJ N-_NNP linked_VBD glycosylations_NNS ._.
        Another_DT explanation_NN is_VBZ the_DT extreme_JJ plasticity_NN of_IN HIV_NNP that_WDT allows_VBZ new_JJ viral_JJ variants_NNS to_TO
        evade_VB immune_JJ recognition_NN in_IN the_DT same_JJ way_NN that_IN they_PRP escape_VB from_IN drugs_NNS ._. Moreover_RB ,_,
        superinfection_NN by_IN a_DT second_JJ viral_JJ strain_NN has_VBZ been_VBN documented_VBN in_IN a_DT number_NN of_IN individuals_NNS who_WP
        have_VBP already_RB mounted_VBN immune_JJ responses_NNS to_TO the_DT initial_JJ HIV_NNP infection_NN ._. Yet_RB another_DT problem_NN is_VBZ
        that_IN the_DT AIDS_NNP research_NN community_NN has_VBZ yet_RB to_TO uncover_VB the_DT correlates_NNS of_IN immune_JJ protection_NN in_IN
        vivo_NN ._. Lastly_NNP ,_, proven_VBN vaccine_NN approaches_NNS from_IN the_DT past_JJ have_VBP either_CC failed_VBN (_( whole_JJ killed_VBN
        virus_NN and_CC subunit_NN vaccines_NNS )_) or_CC faced_VBN seemingly_RB insurmountable_JJ regulatory_JJ hurdles_NNS (_( live_VB
        attenuated_JJ virus_NN vaccine_NN )_) ._.
        Given_VBN these_DT daunting_JJ obstacles_NNS ,_, why_WRB have_VBP so_RB many_JJ continued_VBD in_IN the_DT long_JJ struggle_NN to_TO
        develop_VB an_DT HIV_NNP vaccine_NN ?_. The_DT answer_NN must_MD lie_VB ,_, in_IN part_NN ,_, in_IN the_DT noble_JJ cause_NN at_IN hand_NN ._. Yet_RB there_EX
        are_VBP also_RB some_DT encouraging_VBG clinical_JJ and_CC experimental_JJ observations_NNS (_( Figure_NN 1_LS )_) ._. Rare_JJ patients_NNS
        do_VBP control_VB HIV_NNP infection_NN spontaneously_RB ._. Certain_JJ people_NNS remain_VBP virus-negative_JJ despite_IN
        repeated_VBN exposures_NNS ._. That_DT superinfection_NN is_VBZ not_RB more_RBR commonly_RB found_VBD supports_VBZ the_DT notion_NN of_IN
        immune_JJ control_NN ._. Vaccine-mediated_NNP protection_NN against_IN simian_NN immunodeficiency_NN virus_NN is_VBZ indeed_RB
        possible_JJ using_VBG live_VB viruses_NNS attenuated_JJ by_IN specific_JJ mutations_NNS or_CC by_IN pharmacological_JJ
        interventions_NNS ._. Finally_RB ,_, and_CC perhaps_RB most_RBS importantly_RB ,_, HIV_NNP transmission_NN by_IN sex_NN in_IN the_DT
        natural_JJ setting_NN is_VBZ typically_RB inefficient_JJ (_( and_CC thus_RB easier_JJR to_TO block_VB )_) ,_, unlike_IN most_JJS
        experimental_JJ challenge_NN systems_NNS employed_VBN in_IN monkey_NN studies_NNS to_TO date_NN ._. Collectively_RB ,_, these_DT
        findings_NNS provide_VBP a_DT ray_NN of_IN hope_VBP to_TO push_VB on_IN ._.
      
      
        The_DT Enterprise_NNP
        The_DT scientific_JJ strategic_JJ plan_NN of_IN the_DT Enterprise_NNP is_VBZ spot-on_JJ in_IN identifying_VBG the_DT major_JJ
        roadblocks_NNS in_IN HIV_NNP vaccine_NN development_NN ,_, as_RB well_RB as_IN in_IN establishing_VBG the_DT key_JJ scientific_JJ
        priorities_NNS as_IN we_PRP see_VBP them_PRP today_NN [_NN 1_CD ]_NN ._. It_PRP rightly_RB recommends_VBZ the_DT formation_NN of_IN a_DT growing_VBG
        alliance_NN of_IN organizations_NNS to_TO foster_VB a_DT better_RBR collaborative_JJ spirit_NN that_WDT could_MD lead_VB to_TO ,_, among_IN
        other_JJ things_NNS ,_, stronger_JJR political_JJ support_NN and_CC increased_VBN funding_NN ._. The_DT proposed_VBN greater_JJR
        coordination_NN and_CC management_NN ,_, sharing_NN of_IN information_NN ,_, technologies_NNS ,_, and_CC reagents_NNS ,_, and_CC
        harmonization_NN of_IN standards_NNS ,_, assays_NNS ,_, and_CC approaches_NNS could_MD only_RB add_VB to_TO our_PRP$ overall_JJ
        efforts_NNS ._.
        One_PRP might_MD ask_VB ,_, however_RB ,_, whether_IN there_EX are_VBP potential_JJ downsides_NNS to_TO the_DT plan_NN ._. In_IN the_DT name_NN
        of_IN continuing_VBG this_DT important_JJ dialogue_NN ,_, I_PRP would_MD like_VB to_TO offer_VB one_CD general_JJ concern_NN ._. Arguably_RB ,_,
        the_DT reason_NN for_IN the_DT lack_NN of_IN an_DT effective_JJ HIV_NNP vaccine_NN today_NN is_VBZ rooted_VBN in_IN the_DT basic_JJ problems_NNS
        posed_VBN by_IN the_DT virus_NN itself_PRP ._. What_WP we_PRP need_VBP foremost_RB are_VBP new_JJ scientific_JJ solutions_NNS ,_, although_IN a_DT
        prim_JJ and_CC proper_JJ “ process_NN and_CC structure_NN” in_IN our_PRP$ approach_NN will_MD be_VB helpful_JJ ._. The_DT needed_VBN
        breakthroughs_NNS to_TO develop_VB a_DT vaccine_NN will_MD likely_RB emerge_VB from_IN the_DT creativity_NN of_IN scientists_NNS
        doing_VBG fundamental_JJ research_NN that_WDT is_VBZ free_JJ of_IN preconceived_JJ biases_NNS ._. It_PRP is_VBZ my_PRP$ contention_NN that_IN
        great_JJ new_JJ ideas_NNS are_VBP as_IN likely_JJ to_TO come_VB from_IN curiosity-driven_JJ basic_JJ studies_NNS as_IN from_IN the_DT
        mission-oriented_JJ approach_NN that_WDT is_VBZ represented_VBN by_IN the_DT new_JJ proposal_NN ._. Therefore_RB ,_, the_DT
        leadership_NN of_IN the_DT Enterprise_NNP must_MD safeguard_VB against_IN the_DT kind_NN of_IN “ group_NN think_VBP” that_WDT is_VBZ so_RB
        pervasive_JJ in_IN large_JJ collaborative_JJ endeavors_NNS of_IN this_DT nature_NN ._. The_DT views_NNS of_IN a_DT small_JJ number_NN of_IN
        researchers_NNS ,_, no_DT matter_NN how_WRB smart_JJ or_CC accomplished_VBN ,_, must_MD not_RB supersede_VB the_DT collective_JJ wisdom_NN
        of_IN the_DT scientific_JJ community_NN at_IN large_JJ ._.
        No_DT doubt_NN important_JJ contributions_NNS will_MD be_VB made_VBN by_IN scientists_NNS working_VBG outside_IN of_IN the_DT
        Enterprise_NNP ._. Measures_NNS should_MD be_VB taken_VBN to_TO ensure_VB that_IN their_PRP$ views_NNS and_CC approaches_NNS ,_, even_RB if_IN
        deemed_VBN unconventional_JJ ,_, are_VBP not_RB stifled_JJ by_IN the_DT newly_RB established_VBN system_NN ._. Likewise_RB ,_, their_PRP$
        research_NN support_NN should_MD not_RB be_VB compromised_VBN because_IN the_DT creation_NN of_IN the_DT Enterprise_NNP
        concentrates_VBZ the_DT funding_NN into_IN the_DT hands_NNS of_IN a_DT relatively_RB small_JJ number_NN of_IN designated_VBN
        scientists_NNS ._. To_TO me_PRP this_DT is_VBZ a_DT serious_JJ risk_NN given_VBN the_DT current_JJ “ flat_JJ funding_NN” at_IN the_DT National_NNP
        Institutes_NNPS of_IN Health_NNP ._.
      
      
        The_DT Future_NNP
        The_DT authors_NNS of_IN the_DT “ The_DT Global_NNP HIV_NNP /_NN AIDS_NNP Vaccine_NNP Enterprise_NNP :_: Scientific_NNP Strategic_NNP Plan_NNP”
        have_VBP laid_VBN out_RP a_DT timely_JJ and_CC insightful_JJ plan_NN to_TO address_VB perhaps_RB the_DT greatest_JJS public-health_NN
        need_NN of_IN the_DT millennium_NN ._. This_DT document_NN and_CC its_PRP$ later_RB revisions_NNS will_MD serve_VB as_IN useful_JJ
        guideposts_NNS for_IN the_DT AIDS_NNP vaccine_NN development_NN effort_NN for_IN years_NNS to_TO come_VB ._. To_TO be_VB successful_JJ in_IN
        this_DT mission_NN ,_, our_PRP$ research_NN community_NN will_MD ultimately_RB need_VB a_DT specific_JJ “ scientific_JJ blueprint_NN”
        for_IN making_VBG an_DT HIV_NNP vaccine_NN ._. That_DT day_NN will_MD come_VB only_RB after_IN we_PRP get_VBP another_DT shot_NN in_IN the_DT arm_NN ,_,
        infusing_VBG us_PRP with_IN new_JJ knowledge_NN and_CC know-how_NN ._. Is_VBZ there_EX any_DT doubt_NN that_IN we_PRP need_VBP to_TO redouble_JJ
        our_PRP$ investment_NN in_IN basic_JJ research_NN on_IN the_DT challenges_NNS posed_VBN by_IN HIV_NNP ?_.
      
    
  
